ESLA — Estrella Immunopharma, Inc.

Healthcare • Biotechnology

$2.33

▲ 0.46 (—%)

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Insider Activity Congress Trades Company Site ↗

Company

Ticker: ESLA
Exchange
Sector: Healthcare
Industry: Biotechnology
Country: US
CEO: Cheng Liu
Employees
Website: www.estrellabio.com

Price

3M 1Y 5Y ALL

Showing 1Y history. Source: FMP “historical price full”.

Prev Close: $1.87
Day High: $2.42
Day Low: $1.85
52w High: $2.42
52w Low: $0.63
Volume: 854,755
Avg Volume
Beta: 0.393

Key Metrics

Market Cap: 86.4M
P/E
P/B
P/S
EV/EBITDA
ROE
Net Margin
Div Yield
FCF/Share

* TTM/most recent where available